Dr. Meriem Bouslouk-Marx is an expert on the benefit assessment of new innovative medicines, specialised in rare diseases. With her company MBM Future Health she offers consultancy services to industry, primarily on the AMNOG procedure but also on wider challenges facing healthcare in Germany. The German law AMNOG introduced in 2011 made benefit assessment of new innovative medicines mandatory. Dr. Bouslouk-Marx has comprehensive experience in this field: She joined the Federal Joint Committee (G-BA), Germany’s top health policy body, as part of the initial small AMNOG team. In this position she advised applicant companies on evidence requirements and prepared binding national reimbursement decisions. A particular focus from the outset was on new EMA-approved orphan drugs. She co-ordinated their specific health policy procedure within and outside of  the G-BA.

Dr. Bouslouk-Marx has been a lecturer at EMAUD for more than 10 years.